152 related articles for article (PubMed ID: 1948090)
1. A survey of the clinical experience with dermatan sulfate.
Gianese F; Lucchelli PE
Semin Thromb Hemost; 1991; 17 Suppl 2():199-204. PubMed ID: 1948090
[No Abstract] [Full Text] [Related]
2. Antithrombotic activity of Desmin 370. Comparison with a high molecular weight dermatan sulfate.
Barbanti M; Calanni F; Babbini M; Bergonzini G; Parma B; Marchi E; Wassermann A
Thromb Res; 1993 Sep; 71(5):417-22. PubMed ID: 8236168
[No Abstract] [Full Text] [Related]
3. Pharmacological actions of sulodexide.
Ofosu FA
Semin Thromb Hemost; 1998; 24(2):127-38. PubMed ID: 9579633
[TBL] [Abstract][Full Text] [Related]
4. Unbalanced effects of dermatan sulfates with different sulfation patterns on coagulation, thrombosis and bleeding.
Vicente CP; Zancan P; Peixoto LL; Alves-Sá R; Araújo FS; Mourão PA; Pavão MS
Thromb Haemost; 2001 Nov; 86(5):1215-20. PubMed ID: 11816710
[TBL] [Abstract][Full Text] [Related]
5. Molecular and functional heterogeneity in dermatan sulfate preparations.
Fareed J; Hoppensteadt D; Walenga JM; Ahsan A; Coyne E; Breddin HK
Semin Thromb Hemost; 1991; 17 Suppl 2():174-80. PubMed ID: 1948088
[No Abstract] [Full Text] [Related]
6. [Dermatan sulfate and the prevention of experimental venous thrombosis].
Desnoyers P; Bara L; Samama M
Pathol Biol (Paris); 1989 Jun; 37(6):759-67. PubMed ID: 2674877
[TBL] [Abstract][Full Text] [Related]
7. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate, and heparin.
Hoppensteadt D; Racanelli A; Walenga JM; Fareed J
Semin Thromb Hemost; 1989 Oct; 15(4):378-85. PubMed ID: 2530633
[No Abstract] [Full Text] [Related]
8. Effects of antithrombin and heparin cofactor II levels on anticoagulation with Intimatan.
Tanaka KA; Szlam F; Vinten-Johansen J; Cardin AD; Levy JH
Thromb Haemost; 2005 Oct; 94(4):808-13. PubMed ID: 16270635
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological and clinical studies with Lomoparan, a low molecular weight glycosaminoglycan.
Nurmohamed MT; Fareed J; Hoppensteadt D; Walenga JM; ten Cate JW
Semin Thromb Hemost; 1991; 17 Suppl 2():205-13. PubMed ID: 1948091
[No Abstract] [Full Text] [Related]
10. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of the antithrombotic action of dermatan sulphate by small amounts of heparin.
Thomas DP; Gray E; Merton RE
Thromb Haemost; 1990 Oct; 64(2):290-3. PubMed ID: 2270536
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with a new antithrombotic (dermatan sulfate) in chronic hemodialysis patients.
Nurmohamed MT; Knipscheer HC; Stevens P; Krediet RT; Roggekamp MC; Berckmans RJ; ten Cate JW
Clin Nephrol; 1993 Mar; 39(3):166-71. PubMed ID: 8462205
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic profile of sulfamino-galactosaminoglycans.
Pescador R; Porta R; Mantovani M; Prino G; Casu B; Naggi A; Torri G; Walenga JM; Hoppensteadt DA; Fareed J
Semin Thromb Hemost; 1991; 17 Suppl 1():74-9. PubMed ID: 1906197
[No Abstract] [Full Text] [Related]
14. Antithrombotic properties of dermatan sulphate (MF 701) in haemodialysis for chronic renal failure.
Ryan KE; Lane DA; Flynn A; Ireland H; Boisclair M; Shepperd J; Curtis JR
Thromb Haemost; 1992 Nov; 68(5):563-9. PubMed ID: 1455403
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of thrombin inhibition by heparin cofactor II and antithrombin in the presence of the ray (Raja radula) skin dermatan sulfate.
Ben Mansour M; Dhahri M; Vénisse L; Jandrot-Perrus M; Chaubet F; Maaroufi RM
Thromb Res; 2009 Apr; 123(6):902-8. PubMed ID: 19046760
[TBL] [Abstract][Full Text] [Related]
16. Is heparin the ideal anticoagulant for cardiopulmonary bypass? Dermatan sulphate may be an alternate choice.
Brister SJ; Ofosu FA; Heigenhauser GJ; Gianese F; Buchanan MR
Thromb Haemost; 1994 Apr; 71(4):468-73. PubMed ID: 8052965
[TBL] [Abstract][Full Text] [Related]
17. Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers.
Harenberg J; Jeschek M; Acker M; Malsch R; Huhle G; Heene DL
Blood Coagul Fibrinolysis; 1996 Jan; 7(1):49-56. PubMed ID: 8845462
[TBL] [Abstract][Full Text] [Related]
18. The direct thrombin inhibitor hirudin.
Greinacher A; Warkentin TE
Thromb Haemost; 2008 May; 99(5):819-29. PubMed ID: 18449411
[TBL] [Abstract][Full Text] [Related]
19. Selective and sustained inhibition of surface-bound thrombin activity by intimatan/heparin cofactor II and its relevance to assessing systemic anticoagulation in vivo, ex vivo and in vitro.
Buchanan MR; Maclean GA; Brister SJ
Thromb Haemost; 2001 Sep; 86(3):909-13. PubMed ID: 11583326
[TBL] [Abstract][Full Text] [Related]
20. Human pharmacokinetics and pharmacodynamics of MF 701 dermatan sulfate administered by continuous intravenous infusion.
Agnelli G; Cosmi B; Renga C; Federici F; Nenci GG; Houin G; Gianese F
Thromb Haemost; 1990 Oct; 64(2):256-9. PubMed ID: 2270533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
